Programing the Body to Make Its Own Medicine with Gene Therapy

Ken Mills, CEO of RegenxBio, discusses wet-age macular degeneration, the company’s collaboration with AbbVie, and the potential to alter the way patients with this and other eye conditions are treated by using a gene therapy that gets the body to produce a VEGF inhibitor.